Found: 125
Select item for more details and to access through your institution.
Coronavirus and the Cancer Patient.
- Published in:
- Oncology Practice Management, 2020, v. 10, n. 5, p. 1
- By:
- Publication type:
- Article
Drug development in higher-risk myelodysplastic syndromes.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01171-y
- By:
- Publication type:
- Article
Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
- Published in:
- Journal of Hematology & Oncology, 2020, v. 13, n. 1, p. 1, doi. 10.1186/s13045-020-00929-8
- By:
- Publication type:
- Article
Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes.
- Published in:
- International Journal of Laboratory Hematology, 2021, v. 43, n. 3, p. 426, doi. 10.1111/ijlh.13400
- By:
- Publication type:
- Article
Genetic and molecular characterization of myelodysplastic syndromes and related myeloid neoplasms.
- Published in:
- International Journal of Hematology, 2015, v. 101, n. 3, p. 213, doi. 10.1007/s12185-015-1747-7
- By:
- Publication type:
- Article
Combination strategies in myelodysplastic syndromes.
- Published in:
- International Journal of Hematology, 2012, v. 95, n. 1, p. 26, doi. 10.1007/s12185-011-0987-4
- By:
- Publication type:
- Article
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes.
- Published in:
- Journal of Clinical Investigation, 2015, v. 125, n. 3, p. 1043, doi. 10.1172/JCI78789
- By:
- Publication type:
- Article
Distinctive and common features of moderate aplastic anaemia.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 5, p. 967, doi. 10.1111/bjh.16460
- By:
- Publication type:
- Article
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 2, p. 318, doi. 10.1111/bjh.16336
- By:
- Publication type:
- Article
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 3, p. 404, doi. 10.1111/bjh.16173
- By:
- Publication type:
- Article
Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 935, doi. 10.1111/bjh.15862
- By:
- Publication type:
- Article
Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.
- Published in:
- British Journal of Haematology, 2018, v. 183, n. 1, p. 133, doi. 10.1111/bjh.14907
- By:
- Publication type:
- Article
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.
- Published in:
- British Journal of Haematology, 2017, v. 178, n. 6, p. 906, doi. 10.1111/bjh.14792
- By:
- Publication type:
- Article
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 3, p. 337, doi. 10.1111/bjh.13037
- By:
- Publication type:
- Article
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 2, p. 233, doi. 10.1111/bjh.13035
- By:
- Publication type:
- Article
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 1, doi. 10.1111/bjh.13037
- By:
- Publication type:
- Article
SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 1, doi. 10.1111/bjh.13035
- By:
- Publication type:
- Article
Somatic SETBP1 mutations in myeloid malignancies.
- Published in:
- Nature Genetics, 2013, v. 45, n. 8, p. 942, doi. 10.1038/ng.2696
- By:
- Publication type:
- Article
Descriptive comparison of hospital formulary decisions with published oncology valuation methods.
- Published in:
- Journal of Oncology Pharmacy Practice, 2020, v. 26, n. 4, p. 891, doi. 10.1177/1078155219877927
- By:
- Publication type:
- Article
Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1and CBLMutations Are Present in Systemic Mastocytosis.
- Published in:
- PLoS ONE, 2012, v. 7, n. 8, p. 1, doi. 10.1371/journal.pone.0043090
- By:
- Publication type:
- Article
Older adults with acute myeloid leukemia.
- Published in:
- Current Oncology Reports, 2002, v. 4, n. 5, p. 403, doi. 10.1007/s11912-002-0034-y
- By:
- Publication type:
- Article
Strategies for success in creating an effective multihospital health-system pharmacy and therapeutics committee.
- Published in:
- American Journal of Health-System Pharmacy, 2018, v. 75, n. 7, p. 451, doi. 10.2146/ajhp170531
- By:
- Publication type:
- Article
A phase 1b study of glasdegib + azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes.
- Published in:
- Annals of Hematology, 2022, v. 101, n. 8, p. 1689, doi. 10.1007/s00277-022-04853-4
- By:
- Publication type:
- Article
Correction to: Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
- Published in:
- 2016
- By:
- Publication type:
- journal article
TO PUT THAT INTO CONTEXT.
- Published in:
- Oncology (08909091), 2016, v. 30, n. 4, p. 323
- By:
- Publication type:
- Article
Tricking or Treating Myelodysplastic Syndromes.
- Published in:
- Oncology (08909091), 2011, v. 25, n. 6, p. 488
- By:
- Publication type:
- Article
Health-Related Quality of Life Outcomes in Patients with Myelodysplastic Syndromes with Ring Sideroblasts Treated with Luspatercept in the MEDALIST Phase 3 Trial.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 1, p. 27, doi. 10.3390/jcm11010027
- By:
- Publication type:
- Article
Invariant patterns of clonal succession determine specific clinical features of myelodysplastic syndromes.
- Published in:
- Nature Communications, 2019, v. 10, n. 1, p. 1, doi. 10.1038/s41467-019-13001-y
- By:
- Publication type:
- Article
Active Treatment Strategies Improving Outcomes in Patients with Myelodysplastic Syndromes with the Deletion 5q Abnormality.
- Published in:
- Clinical Cancer Update, 2008, v. 2, n. 1, p. 58, doi. 10.3816/CCU.2008.n.010
- By:
- Publication type:
- Article
Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review.
- Published in:
- PLoS ONE, 2021, v. 16, n. 3, p. 1, doi. 10.1371/journal.pone.0249087
- By:
- Publication type:
- Article
New Data with Arsenic Trioxide in Leukemias and Myelodysplastic Syndromes.
- Published in:
- Clinical Lymphoma & Myeloma, 2007, v. 8, p. S7
- By:
- Publication type:
- Article
Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.
- Published in:
- Communications Biology, 2020, v. 3, n. 1, p. N.PAG, doi. 10.1038/s42003-020-01220-9
- By:
- Publication type:
- Article
Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
- Published in:
- Cancer Medicine, 2021, v. 10, n. 2, p. 447, doi. 10.1002/cam4.3608
- By:
- Publication type:
- Article
Azacitidine in Myelodysplastic Syndromes: A Viewpoint by Mikkael A. Sekeres.
- Published in:
- Drugs, 2005, v. 65, n. 13, p. 1790, doi. 10.2165/00003495-200565130-00006
- By:
- Publication type:
- Article
Ribosomal S6 Kinase and AKT Phosphorylation as Pharmacodynamic Biomarkers in Patients With Myelodysplastic Syndrome Treated With RAD001.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase I Study Assessing the Safety and Tolerability of Barasertib (AZD1152) With Low-Dose Cytosine Arabinoside in Elderly PatientsWith AML.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 5, p. 559, doi. 10.1016/j.clml.2013.03.019
- By:
- Publication type:
- Article
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML.
- Published in:
- 2013
- By:
- Publication type:
- journal article
A Phase II Trial of Gemcitabine and Mitoxantrone for Patients With Acute Myeloid Leukemia in First Relapse.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 6, p. 473, doi. 10.3816/CLML.2010.n.082
- By:
- Publication type:
- Article
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia.
- Published in:
- European Journal of Haematology, 2012, v. 89, n. 4, p. 288, doi. 10.1111/j.1600-0609.2012.01825.x
- By:
- Publication type:
- Article
Survival and Predictors of Outcome in Patients With Acute Leukemia Admitted to the Intensive Care Unit.
- Published in:
- Cancer (0008543X), 2008, v. 112, n. 10, p. 2233, doi. 10.1002/cncr.23394
- By:
- Publication type:
- Article
Impact of Remission Induction Chemotherapy on Survival in Older Adults With Acute Myeloid Leukemia.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 8, p. 1752, doi. 10.1002/cncr.22976
- By:
- Publication type:
- Article
The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndromes.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 9, p. 1705, doi. 10.1002/cncr.22602
- By:
- Publication type:
- Article
A Decision analysis to determine the appropriate treatment for low‐risk myelodysplastic syndromesPresented in part at the 47th annual meeting of the American Society of Hematology, December 11, 2005, and published in abstract form.
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 6, p. 1125, doi. 10.1002/cncr.22497
- By:
- Publication type:
- Article
TREATMENT DECISIONS IN OLDER ADULTS WITH ACUTE MYELOID LEUKEMIA.
- Published in:
- Current Medical Literature: Leukemia & Lymphoma, 2005, v. 13, n. 1, p. 1
- By:
- Publication type:
- Article
Coronavirus and the Cancer Patient.
- Published in:
- Journal of Oncology Navigation & Survivorship, 2020, v. 11, n. 5, p. 142
- By:
- Publication type:
- Article
MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S347, doi. 10.1016/S2152-2650(21)01806-1
- By:
- Publication type:
- Article
MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S339, doi. 10.1016/S2152-2650(21)01791-2
- By:
- Publication type:
- Article
Poster: MDS-344: Pevonedistat Plus Azacitidine vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes (MDS): Efficacy and Safety Results from Study P-2001 (NCT02610777).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S227, doi. 10.1016/S2152-2650(21)01430-0
- By:
- Publication type:
- Article